

RUTAN & TUCKER LLP

Attorneys at Law

611 Anton Boulevard, 14th Floor

Costa Mesa California 92626-1998

Mailing Address: Post Office Box 1950, Costa Mesa, California 92628-1950

Telephone: 714.641.5100

Facsimile 714.546.9035

FACSIMILE TRANSMISSIONDATE: **FEBRUARY 4, 2003**

TO:

Hard Copy to Follow via Mail: **NO**

NAME	FAX NO.	PHONE NO.
Howard Owens Jr.	703-746-5125	703-306-4538

FROM: **Robert D Fish, Esq.**

RE:

OUR REF: 100848.213102US4	NUMBER OF PAGES, INCLUDING COVER: 6
09/624855	
SPECIFIC MODULATION OF TH1/TH2 CYTOKINE EXPRESSION	
RIBAPHARM - ROBERT TAM	

MESSAGE:

Draft amendment further to our interview this morning.

THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED, AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AGENT RESPONSIBLE TO DELIVER THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU

If there are problems receiving this Fax Transmittal please call 714.641.5100, Ext 1235

2022/XX-
a00/00/00

Patent
100848.213102US4

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231**

Inventor: **R. Tam**

Serial No: **09/624855**

Filed: **July 25, 2000**

For: **Specific Modulation of TH1/TH2
Cytokine Expression by Ribavirin in
Activated T-Lymphocytes**

Examiner: **H. Owens**

Art Unit: **1623**

DRAFT AMENDMENT - DO NOT ENTER

The Honorable Commissioner
of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

This paper supplementally responds to the Office Action dated October 1, 2002.

IN THE CLAIMS

A clean listing of all pending claims following amendment herein is set forth below.

2. A method of modulating Type 1 and Type 2 response in activated T cells of a human patient comprising administering ribavirin to the T cells in a dosage to promote the Type 1 response and suppress the Type 2 response, wherein the amount of ribavirin added provides a concentration of about 0.25 - 6.7 $\mu\text{g/ml}$ in a medium supporting the lymphocytes.
4. A method of treating a patient having a disease which includes a viral component and a non-viral component, the non-viral component being characterized by reduced Type 1 levels and increased Type 2 levels in activated T-lymphocytes, comprising administering